1. In this observational cohort study of patients with systemic lupus erythematosus, the current use of hydroxychloroquine as a treatment ...
1. For patients with IgA nephropathy (IgAN), long-term use of hydroxychloroquine demonstrated antiproteinuric effects compared to corticosteroids at 24 months. ...
1. For patients with IgA nephropathy (IgAN), long-term use of hydroxychloroquine demonstrated antiproteinuric effects compared to corticosteroids at 24 months. ...
1. In this retrospective cohort study, the incidence of hydroxychloroquine retinopathy was 2.5% at 10 years, increasing to 8.6% at ...
1. No significant decrease in mortality risk was seen in ventilated patients with COVID-19 on remdesivir compared to control. 2. ...
1. Hydroxychloroquine and lopinavir-ritonavir did not significantly decrease COVID-19–associated hospitalization or improve other secondary clinical outcomes. Evidence Rating Level: 1 ...
1. Postexposure hydroxychloroquine therapy did not prevent coronavirus disease 2019 (Covid-19) infection in exposed healthy individuals. 2. Hydroxychloroquine treatment after ...
1. Postexposure hydroxychloroquine therapy did not prevent coronavirus disease 2019 (Covid-19) infection in exposed healthy individuals. 2. Hydroxychloroquine treatment after ...
1. The addition of azithromycin to standard of care, which included hydroxychloroquine, did not improve clinical outcomes compared to standard ...
1. Hydroxychloroquine use in hospitalized and tocilizumab use in ICU lab-positive COVID-19 patients were not been associated with decreased death. ...
